These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3034850)

  • 1. Clinical efficacy and safety of sulbactam/ampicillin in patients suffering from chronic liver disease.
    Galante D; Esposito S; Barba D; Ruffilli MP
    J Antimicrob Chemother; 1987 Apr; 19(4):527-32. PubMed ID: 3034850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use.
    Lees L; Milson JA; Knirsch AK; Greenhalgh K
    Rev Infect Dis; 1986; 8 Suppl 5():S644-50. PubMed ID: 3026019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
    Campoli-Richards DM; Brogden RN
    Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ampicillin/sulbactam (Unasyn).
    Med Lett Drugs Ther; 1987 Aug; 29(747):79-81. PubMed ID: 3039328
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections.
    Akova M; Ozcebe O; Güllü I; Unal S; Gür D; Akalin S; Tokgözoglu M; Telatar F; Akalin HE
    J Chemother; 1996 Aug; 8(4):284-9. PubMed ID: 8873834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-comparative study of parenteral ampicillin and sulbactam in intra-thoracic and intra-abdominal infections.
    Mehtar S; Croft RJ; Hilas A
    J Antimicrob Chemother; 1986 Mar; 17(3):389-96. PubMed ID: 3009384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of aminopenicillins combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated from patients with complicated urinary tract infections.
    Naber KG; Wittenberger R
    Rev Infect Dis; 1986; 8 Suppl 5():S604-8. PubMed ID: 3026011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ampicillin/sulbactam: current status in severe bacterial infections.
    Rafailidis PI; Ioannidou EN; Falagas ME
    Drugs; 2007; 67(13):1829-49. PubMed ID: 17722953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections.
    Reinhardt JF; Johnston L; Ruane P; Johnson CC; Ingram-drake L; MacDonald K; Ward KW; Mathisen G; George WL; Finegold SM
    Rev Infect Dis; 1986; 8 Suppl 5():S569-75. PubMed ID: 3026005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulbactam/ampicillin for treatment of polymicrobial pelvic infections.
    Hemsell DL
    Drugs; 1986; 31 Suppl 2():22-5. PubMed ID: 3013569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, bacteriological and pharmacokinetic results from an open trial of sultamicillin in patients with acute exacerbations of chronic bronchitis.
    Davies BI; Maesen FP; van Noord JA
    J Antimicrob Chemother; 1984 Feb; 13(2):161-70. PubMed ID: 6323377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms.
    Syriopoulou V; Bitsi M; Theodoridis C; Saroglou I; Krikos X; Tzanetou K
    Rev Infect Dis; 1986; 8 Suppl 5():S630-3. PubMed ID: 3026016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.
    Retsema JA; English AR; Girard A; Lynch JE; Anderson M; Brennan L; Cimochowski C; Faiella J; Norcia W; Sawyer P
    Rev Infect Dis; 1986; 8 Suppl 5():S528-34. PubMed ID: 3026001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of parenteral sulbactam/ampicillin versus clindamycin/gentamicin in the treatment of pelvic inflammatory disease.
    Gunning J
    Drugs; 1986; 31 Suppl 2():14-7. PubMed ID: 3013567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of infections caused by ampicillin-resistant pathogens with a combination of ampicillin and CP-45,899.
    Plouffe JF
    Antimicrob Agents Chemother; 1982 Mar; 21(3):519-20. PubMed ID: 6285812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.
    Wexler HM; Harris B; Carter WT; Finegold SM
    Antimicrob Agents Chemother; 1985 May; 27(5):876-8. PubMed ID: 2990330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of sulbactam/ampicillin in Japan.
    Shimada K
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):171S-174S. PubMed ID: 2686916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children.
    Aronoff SC; Scoles PV; Makley JT; Jacobs MR; Blumer JL; Kalamchi A
    Rev Infect Dis; 1986; 8 Suppl 5():S639-43. PubMed ID: 3026018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections. A multicentre trial.
    Güneren MF
    Drugs; 1988; 35 Suppl 7():57-68. PubMed ID: 3065055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.